NEW YORK, Oct. 3 - Quark Biotech said Wednesday that it would use its gene and protein function profiling technology to supply AstraZeneca with potential cancer targets.

Under the terms of the deal, Quark, a Cleveland-based company that conducts most of its research in Israel, will provide AstraZeneca of London with 100 genes and proteins it identifies using its platform, known as BiFAR. The companies will also work together to evaluate and validate the function of these potential targets.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Parabon NanoLabs is partnering with law enforcement to use genetic genealogy approaches to solve cold cases, Buzzfeed News reports.

A Columbia University-led team used emergency contact information from medical records to create family trees and estimate disease heritability.

In Science this week: ancient Southeast Asian genomes provide insight on human migration, and more.

NPR says a new report recommends that former research chimpanzees should be moved to retirement sanctuaries unless that move would shorten their lives.